GOODWILL(SH:688246)2024-08-21 10:09Investment Rating - The report maintains a "Buy" rating for the company [5][6]. Core Views - The company reported a revenue of 300 million yuan for H1 2024, a year-on-year increase of 2.92%, but the net profit attributable to shareholders was a loss of 27 million yuan, compared to a loss of 23 million yuan in H1 2023 [5][6]. - The company is focusing on enhancing key products and new technology development to improve gross margin, achieving a gross margin of 48.03% in H1 2024, an increase of 2.51 percentage points year-on-year [5][6]. - The company emphasizes internal control management and personnel efficiency, with a decrease in total staff by 6.61% and an increase in revenue per employee from 146,300 yuan in H1 2023 to 161,200 yuan in H1 2024 [6]. - The company continues to invest in R&D, particularly in AI medical applications, with total R&D expenditure of 122 million yuan in H1 2024, a year-on-year increase of 0.20% [6]. - The company has a leading market share in electronic medical records, maintaining its position for 10 consecutive years, which supports its long-term growth outlook [6]. Financial Summary - For 2024, the company expects total revenue of 856 million yuan, with a year-on-year growth rate of 23.2% [7]. - The net profit forecast for 2024 is 104 million yuan, representing a significant recovery from the previous year's loss [7]. - The gross margin is projected to improve to 52.3% in 2024, with a gradual increase expected in subsequent years [7][8]. - The earnings per share (EPS) is anticipated to be 0.76 yuan in 2024, increasing to 1.54 yuan by 2026 [7][8].